Adverse effects of vaccinations and potential therapies against COVID-19

IF 0.2 Q4 ALLERGY
K. Wasiak, P. Rieske
{"title":"Adverse effects of vaccinations and potential therapies against \nCOVID-19","authors":"K. Wasiak, P. Rieske","doi":"10.5114/pja.2022.114392","DOIUrl":null,"url":null,"abstract":"Publication indicates that antiviral therapies are definitely more harmful and less effective as well as less accessible than vaccinations. Antiviral therapies are generally not effective in phase II and III of the disease. The use of antiviral therapies in all patients would doom them to many side effects, and only 10% of patients go from phase I to phase II and require such treatment. The chance of curing COVID-19 patients in phase II and III of the disease is rapidly declining. Vaccinations, on the other hand, are very effective. Confirmed AEFI are rare and intensive research is underway to elucidate their etiopathogenesis. From a biotechnological point of view, vaccination leads to the production of CAR-T-like immunotherapy or monoclonal antibodies, that work from the 1st day of infection, not from the first day of symptom onset, when patients can start some pharmacological therapy. In the case of COVID-19, a clear advantage of vaccination over pharmacological therapy has emerged. Nevertheless, because vaccination may not be effective for all patients, working on therapy should also be intensively carried out. Proper pharmacotherapy administration depends on the quick cooperation of diagnosticians with doctors. It also depends on the development of tests to select therapies and determine in whom a disease such as COVID-19 will change from phase I to phase II. Vaccinated patients will probably respond better to treatments.","PeriodicalId":7469,"journal":{"name":"Alergologia Polska - Polish Journal of Allergology","volume":"1 1","pages":""},"PeriodicalIF":0.2000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alergologia Polska - Polish Journal of Allergology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/pja.2022.114392","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

Abstract

Publication indicates that antiviral therapies are definitely more harmful and less effective as well as less accessible than vaccinations. Antiviral therapies are generally not effective in phase II and III of the disease. The use of antiviral therapies in all patients would doom them to many side effects, and only 10% of patients go from phase I to phase II and require such treatment. The chance of curing COVID-19 patients in phase II and III of the disease is rapidly declining. Vaccinations, on the other hand, are very effective. Confirmed AEFI are rare and intensive research is underway to elucidate their etiopathogenesis. From a biotechnological point of view, vaccination leads to the production of CAR-T-like immunotherapy or monoclonal antibodies, that work from the 1st day of infection, not from the first day of symptom onset, when patients can start some pharmacological therapy. In the case of COVID-19, a clear advantage of vaccination over pharmacological therapy has emerged. Nevertheless, because vaccination may not be effective for all patients, working on therapy should also be intensively carried out. Proper pharmacotherapy administration depends on the quick cooperation of diagnosticians with doctors. It also depends on the development of tests to select therapies and determine in whom a disease such as COVID-19 will change from phase I to phase II. Vaccinated patients will probably respond better to treatments.
针对COVID-19疫苗接种的不良影响和潜在疗法
出版物表明,抗病毒疗法肯定比疫苗更有害,效果更差,也更难以获得。抗病毒治疗通常在疾病的II期和III期无效。在所有患者中使用抗病毒治疗将导致许多副作用,只有10%的患者从第一阶段进入第二阶段并需要这种治疗。新冠肺炎二期和三期患者的治愈机会正在迅速下降。另一方面,接种疫苗是非常有效的。确诊的急性脑损伤非常罕见,目前正在进行深入的研究以阐明其发病机制。从生物技术的角度来看,疫苗接种导致产生car - t样免疫疗法或单克隆抗体,这些抗体从感染的第一天起起作用,而不是从症状出现的第一天起起作用,此时患者可以开始一些药物治疗。就COVID-19而言,疫苗接种明显优于药物治疗。然而,由于疫苗接种可能并非对所有患者都有效,因此也应集中开展治疗工作。适当的药物治疗管理取决于诊断医师与医生的快速合作。这还取决于测试的发展,以选择治疗方法,并确定COVID-19等疾病将从第一阶段转变为第二阶段。接种疫苗的患者可能会对治疗有更好的反应。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
50.00%
发文量
18
期刊介绍: Alergologia Polska - Polish Journal of Allergology is aimed mainly at allergologists, but also medical doctors working in related fields, such as otolaryngology, pulmonology, and dermatology. The main goal of the journal is to ensure rapid publication of important research papers and interesting case studies from the following areas: allergology, diagnostics, therapy of allergic diseases, in particular in the area of immunotherapy, rhinitis, asthma. The Editorial Board accepts for publication original papers, case studies and letters to the Editor. We also publish review articles (both commissioned and those agreed upon with the Editor-in-Chief), articles dealing with standards of medical practice, as well as special issues. The journal is published quarterly. We guarantee short review times (up to two weeks) and immediate publication on-line upon Editor acceptance.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信